Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 0.56 |
| ▸ | FCER2 | P06734 | 2/20 | 0.56 |
| ▸ | GNPAT | O15228 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 13/20 | 0.52 |
| ▸ | MMP3 | P08254 | 7/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.51 |
| ▸ | MMP8 | P22894 | 4/20 | 0.51 |
| ▸ | MMP7 | P09237 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7762294 | 1.00 | MMP1 (0.56) | MMP1FCER2GNPATMMP2MMP3 | |
| SCHEMBL7439020 | 0.86 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL4428864 | 0.86 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7439018 | 0.86 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL6846291 | 0.86 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL4428861 | 0.86 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL21988101 | 0.83 | MMP1 (0.63) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL28222727 | 0.83 | MMP1 (0.56) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL17598277 | 0.82 | GNPAT (0.56) | GNPAT | |
| SCHEMBL93440 | 0.82 | GNPAT (0.58) | GNPATMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1994007527-A2 | VASOACTIVE PEPTIDE INHIBITION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |